Brainstorm Cell Therapeutics Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Chaim Lebovits
- Full Time Employees
- 27
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1325 Avenue of Americas New York City NY United States of America 10019
- IPO Date
- Oct 7, 2003
- CIK
- 0001137883
- Website
- brainstorm-cell.com
- Similar Companies
- Business
- BrainStorm Cell Therapeutics Inc. (OTCQ:BCLI), a clinical-stage biotechnology company founded in 2000 and headquartered in New York with operations in Israel, develops autologous mesenchymal stem cell therapies for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis, and Alzheimer's disease; its lead product candidate NurOwn (debamestrocel), an investigational MSC-NTF cell therapy administered intrathecally or intramuscularly, secretes neurotrophic factors such as GDNF, BDNF, VEGF, HGF, and Galectin-1 to modulate neuroinflammation, promote neuronal survival, and enhance neurological function. The company targets patients with unmet needs in these indications through its proprietary NurOwn platform, which processes patient-derived bone marrow mesenchymal stem cells into neurotrophic factor-secreting cells. Recent developments include FDA clearance in May 2025 for a Phase 3b ALS trial, a manufacturing letter of intent with Minaris Advanced Therapies in May 2025 and memorandum of understanding with Pluri Inc. in November 2024 for NurOwn production, Nasdaq delisting with transition to OTCQB in July 2025, new expanded access program data in June 2025 showing 90% survival over five years in a cohort, and FDA citizen petition review in July 2025 supporting NurOwn's evidence.
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Passes Above 200-Day Moving Average – Should You Sell?
Brainstorm Cell Therapeutics (BCLI) Expected to Announce Quarterly Earnings on Monday
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials